Fusion Antibodies plc announces that it has been informed by Alan Mawson, a Non-Executive Director of the Company, that on 24 September 2018 he purchased 8,500 ordinary shares in the Company (“Ordinary Shares”) at a price of 67 pence per Ordinary Share via his personal pension scheme.
Fusion Antibodies plc (AIM: FAB), a contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces that it has been informed by Alan Mawson, a Non-Executive Director of the Company, that on 24 September 2018 he purchased 8,500 ordinary shares in the Company (“Ordinary Shares”) at a price of 67 pence per Ordinary Share via his personal pension scheme. Following this purchase, Mr Mawson has a direct beneficial interest in 38,988 Ordinary Shares, equivalent to 0.18% of the Company’s issued share capital. Alan Mawson is also a non-executive director of Clarendon Fund Managers Limited (“Clarendon”) and sits on Clarendon’s investment committee. Clarendon is the fund manager for Nitech Growth Fund LP which holds 358,850 Ordinary Shares and Viridian Growth Fund LP which holds 1,831,500 Ordinary Shares.
In addition, the Company has been informed that today Richard Buick, Chief Technical Officer of the Company has purchased 3,000 Ordinary Shares at a price of 70.42 pence per Ordinary Share. Following this purchase, Richard Buick holds 515,125 Ordinary Shares in the Company, representing approximately 2.33 per cent. of the Company’s issued share capital.
The Company has also been informed that today Sonya Ferguson, Non-Executive Director of the Company has purchased 15,307 Ordinary Shares at a price of 65 pence per Ordinary Share. Following this purchase, Sonya Ferguson holds 30,900 Ordinary Shares in the Company, representing approximately 0.14 per cent. of the Company’s issued share capital.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Dr Alan Mawson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies PLC | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 4p each in Fusion Antibodies PLC Identification code (ISIN) for Fusion Antibodies PLC ordinary shares: GB00BDQZGK16 | ||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | n/a | ||||
| e) | Date of the transaction | 24 September 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, XLON | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Dr Richard John Buick |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Technical Officer |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Fusion Antibodies PLC |
| b) | ||
